Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Regeneron adopts Veeva Vault CRM to boost AI-driven commercial insights and treatment access.

REGN

$810.37

-$4.42 -0.54%

Regeneron adopts Veeva Vault CRM to boost AI-driven commercial insights and treatment access.

Market News

25 Aug 2026

PRNewsWire

View Source

Bullish

Regeneron Pharmaceuticals has chosen Veeva Vault CRM globally to enhance its commercial operations by generating Commercial Evidence through AI-powered field engagement. This platform will help Regeneron's commercial teams access critical information faster, uncover barriers to treatment adoption, and improve patient access to its medicines. The move strengthens the strategic partnership between Regeneron and Veeva Systems, with Vault CRM capturing valuable insights from field interactions that were previously missed. This adoption supports Regeneron's mission to deliver life-transforming medicines efficiently to patients in need.

More News (REGN)

Regeneron boosts growth with strong Dupixent sales and FDA approval of Pasatru.

Regeneron Pharmaceuticals ended August positively as its Dupixent sales surged to €5.15 billion in Q2, up 23.6% sequentially, offsetting declines in Eylea sales due to biosimilar competition. Additionally, the FDA approved Pasatru on August 19 for tr...

Analyst Insights

Bullish

2 days ago